Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effects of endothelin-1 1-31 on cell viabililty and [Ca2+]i in cultured neonatal rat cardiomyocytes

Ren AJ, Yuan X, Lin L, Pan YX, Qing YW, Yuan WJ.

. 2008 ; 57 (3) : 373-378.

Language English Country Czech Republic

We previously found that endothelin-1(1-31) (ET-1(1-31)) exhibited a pro-arrhythmogenic effect in isolated rat hearts. In this study, we further investigated the effects of ET-1(1-31) on a cell viability and observed [Ca(2+)](i) in cultured cardiomyocytes. Cultured neonatal rat cardiomyocytes were treated with 0.1, 1, and 10 nM ET-1(1-31) for 24h in the presence or absence of ET(A) receptor antagonist (BQ(123)) or phosphoramidon, a NEP/ECE inhibitor. Cell injury was evaluated by supernatant lactate dehydrogenase (LDH) assay, superoxide dismutase (SOD) activity, and malondialdehyde (MDA) content. Cell viability was assessed by MTT assay. [Ca(2+)](i) was measured with Fluo-3/AM under a laser confocal microscope. 1) ET-1(1-31) dose-dependently increased LDH release and decreased cell viability. 2) LDH and MDA levels were significantly elevated and SOD activity decreased after administration of 1 nM ET-1(1-31) for 24h, and these changes were markedly attenuated by 1 uM BQ(123). 3) Exposure to 10 nM ET 1(1-31) caused a continuous increase in [Ca(2+)](i) to cultured beating cardiomyocytes and termination of [Ca(2+)](i) transient within 6 min, and this change was reversed by 1 uM BQ(123) and attenuated by 0.5 mM phosphoramidon. These results suggest that ET-1(1-31) could cause cell injury, and that the effect of ET-1(1-31) on [Ca(2+)](i) transients is mainly mediated by ET(A) receptor and partially attributed to the conversion of ET-1(1-31) to ET-1(1-21).

References provided by Crossref.org

Bibliography, etc.

Lit.: 13

000      
00000naa 2200000 a 4500
001      
bmc07520569
003      
CZ-PrNML
005      
20111210131157.0
008      
090403s2008 xr e eng||
009      
AR
024    7_
$a 10.33549/physiolres.931168 $2 doi
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ren, A. J.
245    10
$a Effects of endothelin-1 1-31 on cell viabililty and [Ca2+]i in cultured neonatal rat cardiomyocytes / $c Ren AJ, Yuan X, Lin L, Pan YX, Qing YW, Yuan WJ.
314    __
$a Department of Physiology, College of Basic Medical Sciences, Second Military Medical University, Shanghai
504    __
$a Lit.: 13
520    9_
$a We previously found that endothelin-1(1-31) (ET-1(1-31)) exhibited a pro-arrhythmogenic effect in isolated rat hearts. In this study, we further investigated the effects of ET-1(1-31) on a cell viability and observed [Ca(2+)](i) in cultured cardiomyocytes. Cultured neonatal rat cardiomyocytes were treated with 0.1, 1, and 10 nM ET-1(1-31) for 24h in the presence or absence of ET(A) receptor antagonist (BQ(123)) or phosphoramidon, a NEP/ECE inhibitor. Cell injury was evaluated by supernatant lactate dehydrogenase (LDH) assay, superoxide dismutase (SOD) activity, and malondialdehyde (MDA) content. Cell viability was assessed by MTT assay. [Ca(2+)](i) was measured with Fluo-3/AM under a laser confocal microscope. 1) ET-1(1-31) dose-dependently increased LDH release and decreased cell viability. 2) LDH and MDA levels were significantly elevated and SOD activity decreased after administration of 1 nM ET-1(1-31) for 24h, and these changes were markedly attenuated by 1 uM BQ(123). 3) Exposure to 10 nM ET 1(1-31) caused a continuous increase in [Ca(2+)](i) to cultured beating cardiomyocytes and termination of [Ca(2+)](i) transient within 6 min, and this change was reversed by 1 uM BQ(123) and attenuated by 0.5 mM phosphoramidon. These results suggest that ET-1(1-31) could cause cell injury, and that the effect of ET-1(1-31) on [Ca(2+)](i) transients is mainly mediated by ET(A) receptor and partially attributed to the conversion of ET-1(1-31) to ET-1(1-21).
650    _2
$a zvířata $7 D000818
650    _2
$a novorozená zvířata $7 D000831
650    _2
$a aspartátové endopeptidasy $x antagonisté a inhibitory $x metabolismus $7 D016282
650    _2
$a vápníková signalizace $x účinky léků $7 D020013
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a kultivované buňky $7 D002478
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a endotelin-1 $x analogy a deriváty $x farmakologie $7 D019332
650    _2
$a glykopeptidy $x farmakologie $7 D006020
650    _2
$a L-laktátdehydrogenasa $x metabolismus $7 D007770
650    _2
$a malondialdehyd $x metabolismus $7 D008315
650    _2
$a metaloendopeptidasy $x antagonisté a inhibitory $x metabolismus $7 D008666
650    _2
$a konfokální mikroskopie $7 D018613
650    _2
$a kardiomyocyty $x enzymologie $x metabolismus $x účinky léků $7 D032383
650    _2
$a peptidové fragmenty $x farmakologie $7 D010446
650    _2
$a cyklické peptidy $x farmakologie $7 D010456
650    _2
$a inhibitory proteas $x farmakologie $7 D011480
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a receptor endotelinu A $x metabolismus $7 D044022
650    _2
$a superoxiddismutasa $x metabolismus $7 D013482
650    _2
$a časové faktory $7 D013997
650    _2
$a financování organizované $7 D005381
650    _2
$a antagonisté endotelinového receptoru A $7 D065130
700    1_
$a Yuan, X.
700    1_
$a Lin, L.
700    1_
$a Pan, Y. X.
700    1_
$a Qing, Y. W.
700    1_
$a Yuan, W. J.
773    0_
$w MED00003824 $t Physiological research $g Roč. 57, č. 3 (2008), s. 373-378 $x 0862-8408
856    41
$u http://www.biomed.cas.cz/physiolres/pdf/57/57_373.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 9
990    __
$a 20090403092005 $b ABA008
991    __
$a 20090422153757 $b ABA008
999    __
$a ok $b bmc $g 638373 $s 491172
BAS    __
$a 3
BMC    __
$a 2008 $b 57 $c 3 $d 373-378 $i 0862-8408 $m Physiological research $x MED00003824
LZP    __
$a 2009-13/mkme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...